Literature DB >> 27236639

Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data.

Lu Gaohua1, Sibylle Neuhoff2, Trevor N Johnson2, Amin Rostami-Hodjegan3, Masoud Jamei2.   

Abstract

A 4-compartment permeability-limited brain (4Brain) model consisting of brain blood, brain mass, cranial and spinal cerebrospinal fluid (CSF) compartments has been developed and incorporated into a whole body physiologically-based pharmacokinetic (PBPK) model within the Simcyp Simulator. The model assumptions, structure, governing equations and system parameters are described. The model in particular considers the anatomy and physiology of the brain and CSF, including CSF secretion, circulation and absorption, as well as the function of various efflux and uptake transporters existing on the blood-brain barrier (BBB) and blood-CSF barrier (BCSFB), together with the known parameter variability. The model performance was verified using in vitro data and clinical observations for paracetamol and phenytoin. The simulated paracetamol spinal CSF concentration is comparable with clinical lumbar CSF data for both intravenous and oral doses. Phenytoin CSF concentration-time profiles in epileptic patients were simulated after accounting for disease-induced over-expression of efflux transporters within the BBB. Various 'what-if' scenarios, involving variation of specific drug and system parameters of the model, demonstrated that the 4Brain model is able to simulate the possible impact of transporter-mediated drug-drug interactions, the lumbar puncture process and the age-dependent change in the CSF turnover rate on the local PK within the brain.
Copyright © 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blood-cerebrospinal fluid barrier (BCSFB); Blood–brain barrier (BBB); Brain; Inter-individual variability; In vitro-in vivo extrapolation (IVIVE); Lumbar puncture; Modelling and simulation; Physiologically-based pharmacokinetic (PBPK) model; Transporter

Mesh:

Substances:

Year:  2016        PMID: 27236639     DOI: 10.1016/j.dmpk.2016.03.005

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  26 in total

1.  Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes.

Authors:  Carrie German; Minu Pilvankar; Andrzej Przekwas
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-08-08       Impact factor: 2.745

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Authors:  Nithya Srinivas; Kaitlyn Maffuid; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 3.  Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Authors:  Yumi Yamamoto; Meindert Danhof; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-03-09       Impact factor: 4.009

4.  Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.

Authors:  Jing Li; Jianmei Wu; Xun Bao; Norissa Honea; Youming Xie; Seongho Kim; Alex Sparreboom; Nader Sanai
Journal:  Clin Cancer Res       Date:  2017-09-19       Impact factor: 12.531

Review 5.  In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition.

Authors:  Yukiko Murata; Sibylle Neuhoff; Amin Rostami-Hodjegan; Hiroyuki Takita; Zubida M Al-Majdoub; Kayode Ogungbenro
Journal:  AAPS J       Date:  2022-01-13       Impact factor: 4.009

6.  Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases.

Authors:  Jing Li; Jun Jiang; Xun Bao; Vineet Kumar; Stephen C Alley; Scott Peterson; Anthony J Lee
Journal:  Clin Cancer Res       Date:  2022-08-02       Impact factor: 13.801

7.  Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier.

Authors:  Cody J Peer; Cindy H Chau; William D Figg
Journal:  Clin Cancer Res       Date:  2017-10-10       Impact factor: 12.531

8.  Pharmacokinetic Modeling of the Impact of P-glycoprotein on Ondansetron Disposition in the Central Nervous System.

Authors:  Manting Chiang; Hyun-Moon Back; Jong Bong Lee; Sarah Oh; Tiffany Guo; Simone Girgis; Celine Park; Simon Haroutounian; Leonid Kagan
Journal:  Pharm Res       Date:  2020-09-28       Impact factor: 4.200

9.  Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations.

Authors:  Mohammed A A Saleh; Chi Fong Loo; Jeroen Elassaiss-Schaap; Elizabeth C M De Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-06-17       Impact factor: 2.745

10.  Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling.

Authors:  Laurens F M Verscheijden; Jan B Koenderink; Saskia N de Wildt; Frans G M Russel
Journal:  Arch Toxicol       Date:  2021-07-15       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.